Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4 + T cell responses with a conserved T cell receptor repertoire

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4467-4474

  Bioley, Gilles ^a   Dousset, Christelle ^a   Yeh, Alice ^b   Dupont, Bo ^b   Bhardwaj, Nina ^c   Mears, Gregory ^d   Old, Lloyd J ^b   Ayyoub, Maha ^a   Valmori, Danila ^a,e  

^a Team 12   (France)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 7909; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HLA DR52B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONTANIDE ISA 51; NY ESO 1 ANTIGEN; RECOMBINANT ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE CLONE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPITOPE MAPPING; HLA-DR ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; T-CELL ANTIGEN RECEPTOR SPECIFICITY; VACCINATION;

EID: 67650375847     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0582     Document Type: Article

References (35)

1. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22- 32.
2. Valmori D, DutoitV, L ié nard D, et al. Naturally occurring HLA-A2 restricted CD8+ T cell response to the cancer testis antigen NY-ESO-1in melanoma patients. Cancer Res 2000;60:4499-506.
3. Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000; 191:625 - 30.
4. Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ Tcells. Cancer Res 2000;60:4946- 52.
5. Davis ID, ChenW, Jackson H, et al. Recombinant NYESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) Tcell responses in humans. Proc Natl Acad Sci US A 2004;101:10697-702.
6. Mandic M, Castelli F, Janjic B, et al. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ Tcells from patients with NY-ESO-1-expressing melanoma. J Immunol 2005;174:1751-9.
7. Ayyoub M, Souleimanian NE, Godefroy E, et al. A phenotype based approach for the immune monitoring of NY-ESO-1 specific CD4+ T cell responses in cancer patients. Clin Immunol 2006;118:188-94.
8. Zeng G,Wang X, Robbins PF, Rosenberg SA,Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: associationwith NY-ESO-1 antibody production. Proc Natl Acad Sci US A 2001; 98:3964-9.
9. Valmori D, Souleimanian NE,ToselloV, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1responses and CD8 T cells through cross-priming. Proc Natl Acad Sci US A 2007;104:8947-52.
10. ValmoriD, DutoitV, Lienard D, et al.Tetramer-guided analysis of TCR h-chain usage reveals a large repertoire of Melan-A-specific CD8+ T cells in melanoma patients. J Immunol 2000;165:533-8.
11. Genevee C, Diu A, Nierat J, et al. An experimentally validated panel of subfamily-specific oligonucleotide primers (V a 1-w29/V h 1-w24) for the study of humanT cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol 1992; 22:1261-9.
12. ArdenB, ClarkSP, KabelitzD,MakTW. HumanT-cell receptor variable gene segment families. Immunogenetics 1995;42:455-500.
13. Ayyoub M, Hesdorffer CS, Montes M, et al. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest 2004;113:1225-33.
14. Rimoldi D, Rubio-GodoyV, DutoitV, et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTLe pitopes in melanoma. J Immunol 2000;165: 7253-61.
15. Zarour HM, Maillere B, BrusicV, et al. NY-ESO-1 119 - 143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized byTh1-and Th2-type tumor-reactive CD4+ T cells. Cancer Res 2002;62:213- 8.
16. Valmori D, Qian F, Ayyoub M, et al. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res 2006;12: 398-404.
17. Godefroy E, Scotto L, Souleimanian NE, et al. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol 2006;121:54- 62.
18. Texier C, Pouvelle-Moratille S, Busson M, Charron D, Menez A, Maillere B. Complementarity and redundancy of the binding specificity ofHLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. EurJImmunol 2001;31: 1837-46.
19. CotnerT, Charbonneau H,Mellins E, Pious D. mRNA abundance, rather than differences in subunit assembly, determine differential expression of HLA-DR h 1 and -DR h 3 molecules. J Biol Chem 1989;264: 11107 - 11.
20. Sengar DP, Goldstein R,Toye B, Hampton N. Comprehensive typing of DR52 (DRB3)-associated DRB1 and DRB3 alleles by PCR-RFLP. TissueAntigens1994; 43:286-94.
21. Chen QY, Huang W, She JX, Baxter F, Volpe R, Maclaren NK. HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab 1999;84:3182-6.
22. Oh HH, Kwon SH, Kim CW, et al.Molecular analysis of HLA class II-associated susceptibility to neuroinflammatory diseases in Korean children. J Korean Med Sci 2004;19:426-30.
23. Zabay JM, Marco J, Soler J, et al. Association of HLA-DRB3*0202 and serum IgG antibodies to Chlamydia pneumoniae with essential hypertension in a highly homogeneous population from Majorca (Balearic Islands, Spain). J Hum Hypertens 2005;19: 615- 22.
24. Verreck FA, van de Poel A, Drijfhout JW, Amons R, Coligan JE, Konig F. Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52. Immunogenetics 1996; 43:392-7.
25. Dai S, Crawford F, Marrack P, Kappler JW. The structure of HLA-DR52c: comparison to other HLADRB3 alleles. Proc Natl Acad Sci U S A 2008;105: 11893 - 7.
26. DutoitV,Taub RN, Papadopoulos KP, et al.Multiepitope CD8(+) T cell response to a NY-ESO-1peptide vaccine results in imprecise tumor targeting. JClin Invest 2002;110:1813- 22.
27. Valmori D, Dutoit V, Schnuriger V, et al.Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002;168:4231-40.
28. Chaux P,VantommeV, StroobantV, et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 1999; 189:767-78.
29. Manici S, SturnioloT, ImroMA, et al.Melanoma cells present aMAGE-3 epitope to CD4+ cytotoxicTcells in association with histocompatibility leukocyte antigen DR11. J ExpMed 1999;189:871-6.
30. Levy F,Muehlethaler K, Salvi S, et al. Ubiquitylation of a melanosomal protein by HECT-E3 ligases serves as sorting signal for lysosomal degradation. Mol Biol Cell 2005;16:1777-87.
31. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
32. Qin Z, BlankensteinT. CD4+ Tcell - mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNg receptor expression by nonhematopoietic cells. Immunity 2000;12:677-86.
33. Mumberg D, Monach PA, Wanderling S, et al. CD4(+) Tcells eliminateMHC class II-negative cancer cells in vivo by indirect effects of IFN-g. Proc Natl Acad Sci US A1999;96:8633- 8.
34. Le Gal FA, Ayyoub M, Dutoit V, et al. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother 2005;28:252-7.
35. Kudela P, Janjic B, Fourcade J, et al. Cross-reactive CD4+ T cells against one immunodominant tumorderived epitope in melanoma patients. J Immunol 2007;179:7932-40.